Abbott公司研制出新一代冠状动脉支架

一种新型冠状动脉支架被设计用于提供更好的可视功能以及最可能的输送功能。

这种TriMaxx支架将成为研究药物释放支架（叫做ZoMaxx）的平台，在2005年法国巴黎举办的巴黎血管再通课程(PCR)上进行了展示。这种支架是由美国Abbott血管公司(Redwood City, CA, USA)研制开发的。

TriMaxx冠状动脉支架的支柱(网孔状支架)极其细小，交叉轮廓较低，这种设计便于在动脉中放置支架。在巴黎投放的支架具有全尺寸的基质，支架直径范围在2.25mm~4.0mm之间，长度8mm~28mm之间。Trimaxx是第一种仅有的裸金属支架平台，是由3层不锈钢和钽组成的，这种设计确保在X线荧光扫描中能够具有良好的可视性。

巴西圣保罗Dante Pazzanese医院的Alexandre Abizaid医生指出：“根据我的经验，Abbott公司TriMaxx支架的输送性特别优越，这种产品轮廓细小，X线血管造影清晰可视，使得TriMaxx成为每日应用的有竞争性的产品，适合在特殊病例中进行精确操作。”Abizaid医生是第一位在冠状动脉疾病患者中植入TriMaxx的医生。
 
Next-Generation Coronary Stent
 
A new coronary stent is designed to offer better visibility and the best-possible delivery.

This TriMaxx stent will be the platform for an investigational drug-eluting stent called ZoMaxx, showcased at the Paris Course on Revascularization (PCR) in Paris (France) in May 2005. The stent was developed by Abbott Vascular (Redwood City, CA, USA).

The TriMaxx coronary stent has extremely thin struts (mesh scaffolding) and an ultra-low crossing profile designed to facilitate stent placement in arteries. The stent was launched in Paris with a full matrix of sizes, including stent diameters ranging from 2.25 mm to 4.0 mm, and lengths ranging from 8 mm to 28 mm. Trimaxx is the first and only bare metal stent platform developed with a tri-layer composite of stainless steel and tantalum designed to enable optimal visibility under x-ray fluoroscopy.

“In my experience, Abbott’s TriMaxx stent offers an excellent level of deliverability,” said Alexandre Abizaid, M.D., of Dante Pazzanese Hospital in Sao Paulo (Brazil). “Its thin low-profile design, coupled with the ability to clearly see the product under angiogram (x-ray) should make the TriMaxx a compelling candidate for everyday use and for accurate stent placement in certain challenging cases.” Dr. Abizaid was the first doctor to implant the TriMaxx in patients with diseased coronary arteries.